{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progressive+Muscular+Dystrophy&page=2",
    "query": {
      "condition": "Progressive Muscular Dystrophy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progressive+Muscular+Dystrophy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T07:46:56.720Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01125709",
      "title": "Comparative Study of Clinical Endpoint in DMD: Handheld Myometry (HHM) Versus CINRG Quantitative Measurement System (CQMS)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Cooperative International Neuromuscular Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "6 Years to 18 Years · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2010-01",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2013-01-11",
      "last_synced_at": "2026-05-22T07:46:56.720Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • St Louis, Missouri • Charlotte, North Carolina",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01125709"
    },
    {
      "nct_id": "NCT02964377",
      "title": "Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "(+)- Epicatechin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Craig McDonald, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "17 Years",
        "sex": "MALE",
        "summary": "8 Years to 17 Years · Male only"
      },
      "enrollment_count": 15,
      "start_date": "2016-11",
      "completion_date": "2018-07",
      "has_results": true,
      "last_update_posted_date": "2021-12-21",
      "last_synced_at": "2026-05-22T07:46:56.720Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02964377"
    },
    {
      "nct_id": "NCT05096221",
      "title": "A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "delandistrogene moxeparvovec",
          "type": "GENETIC"
        },
        {
          "name": "placebo",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "7 Years",
        "sex": "MALE",
        "summary": "4 Years to 7 Years · Male only"
      },
      "enrollment_count": 126,
      "start_date": "2021-10-27",
      "completion_date": "2024-10-25",
      "has_results": true,
      "last_update_posted_date": "2025-07-08",
      "last_synced_at": "2026-05-22T07:46:56.720Z",
      "location_count": 23,
      "location_summary": "Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 20 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05096221"
    },
    {
      "nct_id": "NCT03992430",
      "title": "A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Muscular Dystrophy, Duchenne"
      ],
      "interventions": [
        {
          "name": "Eteplirsen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "13 Years",
        "sex": "MALE",
        "summary": "4 Years to 13 Years · Male only"
      },
      "enrollment_count": 160,
      "start_date": "2020-07-13",
      "completion_date": "2026-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-05-22T07:46:56.720Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Gainesville, Florida • Atlanta, Georgia",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03992430"
    },
    {
      "nct_id": "NCT01952028",
      "title": "LAMA2-related Muscular Dystrophy Brain Study",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Cure CMD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 0,
      "start_date": "2013-11",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2018-03-07",
      "last_synced_at": "2026-05-22T07:46:56.720Z",
      "location_count": 1,
      "location_summary": "San Pedro, California",
      "locations": [
        {
          "city": "San Pedro",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01952028"
    },
    {
      "nct_id": "NCT00001871",
      "title": "Study of Muscle Abnormalities in Patients With Specific Genetic Mutations",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cardiomyopathy, Hypertrophic",
        "Muscular Dystrophy, Oculopharyngeal"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 80,
      "start_date": "1999-01",
      "completion_date": "2001-03",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-05-22T07:46:56.720Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001871"
    },
    {
      "nct_id": "NCT03675126",
      "title": "An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Muscular Dystrophy, Duchenne"
      ],
      "interventions": [
        {
          "name": "SRP-5051",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "4 Years and older · Male only"
      },
      "enrollment_count": 15,
      "start_date": "2018-12-19",
      "completion_date": "2021-08-25",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-05-22T07:46:56.720Z",
      "location_count": 7,
      "location_summary": "Hartford, Connecticut • Gulf Breeze, Florida • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03675126"
    },
    {
      "nct_id": "NCT01182324",
      "title": "The PTC124 (Ataluren) Clinical Trial for Duchenne Muscular Dystrophy: Exploration of the Experiences of Parents, Clinician Researchers, and the Industry Sponsor",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 21,
      "start_date": "2010-07-30",
      "completion_date": "2013-06-24",
      "has_results": false,
      "last_update_posted_date": "2018-04-05",
      "last_synced_at": "2026-05-22T07:46:56.720Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01182324"
    },
    {
      "nct_id": "NCT01805024",
      "title": "Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Congenital Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Omigapil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santhera Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "5 Years to 16 Years"
      },
      "enrollment_count": 20,
      "start_date": "2014-12",
      "completion_date": "2018-01-29",
      "has_results": true,
      "last_update_posted_date": "2021-09-24",
      "last_synced_at": "2026-05-22T07:46:56.720Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01805024"
    },
    {
      "nct_id": "NCT02603562",
      "title": "Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Facioscapulohumeral Muscular Dystrophy (FSHD)"
      ],
      "interventions": [
        {
          "name": "ATYR1940",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "aTyr Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "16 Years to 25 Years"
      },
      "enrollment_count": 8,
      "start_date": "2016-03-30",
      "completion_date": "2016-12-12",
      "has_results": true,
      "last_update_posted_date": "2023-10-19",
      "last_synced_at": "2026-05-22T07:46:56.720Z",
      "location_count": 4,
      "location_summary": "Stanford, California • Iowa City, Iowa • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02603562"
    }
  ]
}